A carregar...
Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
We report a woman who developed BIA‐ALCL 9 years after saline implant placement. The lymphoma manifested as a mass lesion associated with axillary lymphadenopathy. She was successfully treated with brentuximab vedotin with minimal toxicity. Brentuximab vedotin may be a promising frontline therapeuti...
Na minha lista:
| Publicado no: | Clin Case Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5889253/ https://ncbi.nlm.nih.gov/pubmed/29636930 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.1382 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|